IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 65.5

Change

-0.12 (-0.18)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.18 (-0.14%)

USD 33.98B
FHLC Fidelity® MSCI Health Care In..

-0.05 (-0.08%)

USD 2.37B
FXH First Trust Health Care AlphaD..

-0.08 (-0.08%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

+0.43 (+0.53%)

USD 0.17B
IDNA iShares Genomics Immunology an..

-0.11 (-0.53%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.06 (-0.06%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.09 (+0.29%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.12 (-0.44%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.34%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.18 (+0.91%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.33% 90% A- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.33% 90% A- 45% F
Trailing 12 Months  
Capital Gain -1.34% 71% C- 39% F
Dividend Return 0.98% 88% B+ 21% F
Total Return -0.36% 71% C- 34% F
Trailing 5 Years  
Capital Gain 24.86% 76% C+ 52% F
Dividend Return 8.65% 95% A 22% F
Total Return 33.51% 86% B+ 45% F
Average Annual (5 Year Horizon)  
Capital Gain 2.50% 67% D+ 50% F
Dividend Return 3.87% 67% D+ 45% F
Total Return 1.37% 100% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 14.15% 62% D 65% D
Risk Adjusted Return 27.39% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike